Enrolling >5,700 Participants for a Global Phase 3 Trial
Velocity enrolled >5,700 participants (14.5% of the trial; 106.5% of the initial target). Compared to other trial sites, Velocity delivered an average of >30% more participants per site.
Velocity achieved its enrollment goal in mid-November, 11 days before the enrollment window closed. Given this success, Velocity was authorized to enroll beyond its initial target.
Enrolling 1,400+ Participants Across 3 Countries for a Phase 3 Flu Vaccine Trial
CSL Seqirus partnered with Velocity to deliver patients in the U.S., U.K., and Germany for a Phase 3 flu vaccine trial. Worldwide, 25 Velocity sites were selected to deliver a significant portion of the trial’s 7,700 participants.
Delivering an Entire Phase 4 Trial: Enrolling 1,000 Participants, Including >45% People of Color
Velocity delivered 100% of a trial’s participants — 1,000 total — >45% of whom identified as people of color.
Enrolling 600+ Participants for a Fully Decentralized Asthma Trial (BATURA)
Avillion and AstraZeneca partnered with Velocity to test a novel asthma treatment for teens and adults as part of the fully decentralized BATURA trial. Targeting people aged 12 and older with asthma, Velocity was selected to support the trial in the U.S.
Doubling the Average Participation Rate of Diverse Populations in Cognivue’s FOCUS Study
Neuroscience company Cognivue enrolled more than double the national average participation rate of diverse populations in its Further the Objective and Clinical Understanding of Cognivue Study (FOCUS) study. Velocity supported the study by enrolling the entirety of the study’s more than 1,500 subjects across 14 sites and 11 states.
Explore more at Velocity
Let's talk about your next trial